Status:
RECRUITING
Donor CHIP and Allogeneic HSCT Outcome
Lead Sponsor:
The University of Hong Kong
Conditions:
Clonal Hematopoiesis
Eligibility:
All Genders
18+ years
Brief Summary
Current data on the impact of donor CHIP on long-term recipient outcome remain largely speculative. Data on the impact of donor CHIP including on allograft function, immunologic dysfunction, graft ver...
Detailed Description
This is a single centre prospective and retrospective cohort study. This study involves allo-HSCT recipients and their donors at Queen Mary Hospital, Hong Kong. Information on the presence of gene mut...
Eligibility Criteria
Inclusion
- Adult aged 18 year or above
- Donor and recipient of allo-HSCT
- In prospective and partial prospective/retrospective case, subjects who have provided a signed written informed consent. In retrospective case, subjects who had provided a previously signed written informed consent on:
- voluntary provision of clinical data, and
- voluntary provision of archived/remaining specimens for genetic analysis, and
- authorizing storage and usage of archived/remaining specimens for any further analysis
Exclusion
- 1\. Autologous peripheral blood stem cells or bone marrow stem cell donors for autologous HSCT
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
850 Patients enrolled
Trial Details
Trial ID
NCT04689750
Start Date
January 1 2021
End Date
December 31 2026
Last Update
October 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Hong Kong
Hong Kong, Hong Kong